

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

**CLARIFICATION ANNOUNCEMENT
IN RELATION TO THE INTERIM RESULTS ANNOUNCEMENT
FOR THE SIX MONTHS ENDED JUNE 30, 2023**

Reference is made to the interim results announcement of RemeGen Co., Ltd.* (榮昌生物製藥(煙台)股份有限公司) (the “**Company**”) for the six months ended June 30, 2023 dated August 21, 2023 (the “**2023 Interim Results Announcement**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meaning as defined in the 2023 Interim Results Announcement.

The Company would like to clarify that due to inadvertent error, page 24 of the 2023 Interim Results Announcement should read as follows (with the correction underlined):

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended 30 June 2023

		2023 (Unaudited) RMB'000	2022 (Unaudited) RMB'000
	Notes		
REVENUE	5	419,073	348,779
Cost of sales		<u>(102,655)</u>	<u>(167,505)</u>
Gross profit		316,418	181,274
Other income and gains		55,013	53,676
Selling and distribution expenses		(350,168)	(149,961)
Administrative expenses		(168,609)	(106,919)
Research and development costs		(540,453)	(449,672)
Impairment losses on financial assets, net		(4,108)	(5,595)
Other expenses		(5,458)	(9,754)
Finance costs		<u>(5,997)</u>	<u>(2,175)</u>
LOSS BEFORE TAX		(703,362)	(489,126)
Income tax expense	6	<u>—</u>	<u>—</u>
LOSS FOR THE PERIOD		<u>(703,362)</u>	<u>(489,126)</u>
Attributable to:			
Owners of the parent		<u>(703,362)</u>	<u>(489,126)</u>
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	8		
Basic/diluted			
— For loss for the period		<u>(1.30)</u>	<u>(0.96)</u>

This clarification announcement is supplemental to and should be read in conjunction with the 2023 Interim Results Announcement. Save as disclosed above, all other information and contents in the 2023 Interim Results Announcement remain unchanged.

The above clerical error will be rectified in the interim report of the Company for the six months ended June 30, 2023 (the “**2023 Interim Report**”). Shareholders of the Company are advised to refer to the full text of the 2023 Interim Report.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive Director

Yantai, PRC
August 22, 2023

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Dr. Ma Lan and Mr. Chen Yunjin as the independent non-executive Directors.

* *For identification purposes only*